NCT00603577 - Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Colorectal Neoplasms

Interventions

DRUG

Placebo

Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).

DRUG

Xaliproden

1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).

Trial Locations (8)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Québec

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Frankfurt

Sanofi-Aventis Administrative Office, Kallithea

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey